{
  "id": "605258f494d57fd87900000c",
  "type": "summary",
  "question": "How is Burke-Fahn-Marsden Dystonia scale used?",
  "ideal_answer": "Burck-Fahn-Marsden Dystonia scale (BBS) is a simple, reliable, and valid measure of disease severity in patients with dystonia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32252836",
    "http://www.ncbi.nlm.nih.gov/pubmed/24461258",
    "http://www.ncbi.nlm.nih.gov/pubmed/23549056",
    "http://www.ncbi.nlm.nih.gov/pubmed/21692107",
    "http://www.ncbi.nlm.nih.gov/pubmed/32796550",
    "http://www.ncbi.nlm.nih.gov/pubmed/28548593",
    "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
    "http://www.ncbi.nlm.nih.gov/pubmed/28661018",
    "http://www.ncbi.nlm.nih.gov/pubmed/32079672",
    "http://www.ncbi.nlm.nih.gov/pubmed/20207700",
    "http://www.ncbi.nlm.nih.gov/pubmed/21147544",
    "http://www.ncbi.nlm.nih.gov/pubmed/33084096",
    "http://www.ncbi.nlm.nih.gov/pubmed/32731476",
    "http://www.ncbi.nlm.nih.gov/pubmed/20697054",
    "http://www.ncbi.nlm.nih.gov/pubmed/27567612",
    "http://www.ncbi.nlm.nih.gov/pubmed/32441447",
    "http://www.ncbi.nlm.nih.gov/pubmed/31954905",
    "http://www.ncbi.nlm.nih.gov/pubmed/15264773",
    "http://www.ncbi.nlm.nih.gov/pubmed/31207377",
    "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
    "http://www.ncbi.nlm.nih.gov/pubmed/33159411",
    "http://www.ncbi.nlm.nih.gov/pubmed/17274034",
    "http://www.ncbi.nlm.nih.gov/pubmed/31817799",
    "http://www.ncbi.nlm.nih.gov/pubmed/26616635",
    "http://www.ncbi.nlm.nih.gov/pubmed/21491490",
    "http://www.ncbi.nlm.nih.gov/pubmed/23408442",
    "http://www.ncbi.nlm.nih.gov/pubmed/27770067",
    "http://www.ncbi.nlm.nih.gov/pubmed/32386250",
    "http://www.ncbi.nlm.nih.gov/pubmed/17608320"
  ],
  "snippets": [
    {
      "text": "To estimate the minimal clinically important difference for the Burke-Fahn-Marsden Dystonia Rating Scale and the 36-Item Short-Form Health Survey in generalized or segmental dystonia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Motor responses were measured with the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32386250",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The primary clinical outcome used was assessed by retrospective video analyses of patients' dystonia symptoms using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32252836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "documenting pre-surgical and post-surgical assessments using the Burke-Fahn-Marsden Dystonia Rating Scale Motor Score (BFMMS) and Burke-Fahn-Marsden Disability Score (BFMDS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32079672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The disease severity was evaluated with Burke-Fahn-Marsden Dystonia Rating Scale and Toronto Western Spasmodic Torticollis Rating Scale.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32731476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ere treated by Gpi-DBS and 11 patients were treated by STN-DBS. All patients were assessed before surgery and at the last follow-up after surgery. The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) including the movement and disability scales was used to evaluate the dystonia severity of the eyes, the mouth, speech, and swallowing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33159411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bipallidal deep brain stimulation (DBS) resulted in a 55% reduction of dystonia severity assessed by the Burke-Fahn-Marsden scale score six months after surgery",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33084096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: The Burke-Fahn-Marsden Dystonia Rating Scale is a universally applied instrument for the quantitative assessment of dystonia in both children and adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tor function was assessed using the Burke-Fahn-Marsden Dystonia Movement and Disability scales and the Barry Albright Dystonia Scale.RE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim is to demonstrate that in some cases of secondary dystonia, the sole use of impairment level measures, such as the Burke-Fahn-Marsden Dystonia Rating Scale, may be insufficient to fully evaluate outcome following deep brain stimulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Deep brain stimulation outcomes are typically reported using impairment-focused measures, such as the Burke-Fahn-Marsden Dystonia Rating Scale, which provide little information about function and participation outcomes or changes in non-motor areas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "mates for the Burke-Fahn-Marsden Dystonia Rating Scale and the 36-Item Short-Form Health Survey may allow more reliable judgment of the clinical relevance of different treatments for segmental and generalized isolated dystonia. \u00a9 2020 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Twenty articles comprising 68 patients with cerebral palsy undergoing deep brain stimulation assessed by the Burke-Fahn-Marsden Dystonia Rating Scale were identified.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23408442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Burke-Fahn-Marsden Dystonia Rating Scale movement score was chosen as the primary outcome measure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23408442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "idated. Deep brain stimulation outcomes are typically reported using impairment-focused measures, such as the Burke-Fahn-Marsden Dystonia Rating Scale, which provide little information about function and participation outcomes or changes in non-motor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "l palsy. Today, the Burke-Fahn-Marsden Dystonia Rating Scale (BFM) is mostly used to assess dystonia in children with inherited dy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32796550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". The Burke-Fahn-Marsden Dystonia Rating Scale-movement (BFM-M) evaluates dystonia impairment, but may not reflect functional ability.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616635",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eas. The aim is to demonstrate that in some cases of secondary dystonia, the sole use of impairment level measures, such as the Burke-Fahn-Marsden Dystonia Rating Scale, may be insufficient to fully evaluate outcome following deep brain stimulati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: The Burke-Fahn-Marsden Dystonia Rating Scale is a universally applied instrument for the quantitative assessment of dystonia in both childre",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ng the movement and disability subscores of the Burke-Fahn-Marsden Dystonia Rating Scale, the authors evaluated the severity of patients' dystonia and related before surgery and at final follow-up during neurostimulation. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28548593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rological status and improvement in motor function resulting from DBS were measured using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). Implantati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15264773",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ts were assessed before surgery and at the last follow-up after surgery using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) which includes both the movement and disability scales. Bilateral ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21147544",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "y and disability were assessed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). Disability sc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reaching speed improved in response to injection, and dystonia scores on the Burke-Fahn-Marsden dystonia scale, the Unified Dystonia Rating Scale, and the Unified Parkinson's Disease Rating Scale improved.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17608320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LTS: Commonly used scales for clinical assessment are the Burke-Fahn-Marsden dystonia rating scale for generalized dystonia and the Toronto Western Spasmodic Torticollis Scale for cervical dystonia. Mo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21692107",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UTCOME MEASURES: The primary outcome measures were the Burke-Fahn-Marsden Dystonia Scale (BFMDS) severity and disability scores, and the secondary outcome measure was the Unified Parkinson Disease Rating Scores.RESUL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20697054",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Hamilton Anxiety Scale (HAMA), and the Hamilton Depression Scale (HAMD) were used to regularly assess changes in the patient's condition after DBS treatment.C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31954905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale was used to evaluate the severity of dystonia at three time points (before surgery, 3 months postoperatively, and the last available follow-up). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31207377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Burke Fahn Marsden Dystonia Rating Scale served as an outcome measure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31817799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he Canadian Occupational Performance Measure (COPM) and Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) were used as primary outcome measures. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461258",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e searched PubMed for studies on genetically confirmed monogenic dystonia treated with GPi DBS documenting pre-surgical and post-surgical assessments using the Burke-Fahn-Marsden Dystonia Rating Scale Motor Score (BFMMS) and Burke-Fahn-Marsden Disability Score (BFMDS). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32079672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: The Burke-Fahn-Marsden Dystonia Rating Scale is a universally applied instrument for the quantitative assessment of dystonia in both children and adults",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he proportion of eye closure time was compared with 3 commonly used clinical rating scales: the Burke-Fahn-Marsden Dystonia Rating Scale, Global Dystonia Rating Scale, and Jankovic Rating Scale.R",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THODS: Case series describing characteristics and outcomes based on the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) scores before and after DBS at 3, 6 and at least 12 months.R",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data on severity of dystonia (Burke Fahn Marsden Dystonia Rating Scale-Motor Scale, Barry Albright Dystonia Scale), disability (Burke Fahn Marsden Dystonia Rating Scale-Disability Scale), quality of life (subjective global rating from 1 to 10 obtained retrospectively from patient and caregiver) as well as data on supportive therapy, concurrent pharmacotherapy, stimulation settings, adverse events and side effects were collected.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207700",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ependent of that, parents scored their children's functional motor development according to the Burke-Fahn-Marsden disability scale in another 52 healthy children (4-16 years of age; 2 boys and 2 girls per year of age). By",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s: In healthy children, assessment of physiologically immature motor performances by the Burke-Fahn-Marsden movement and disability scales showed an association between the outcomes of both scales and age (until 16 years and 12 years of age, \u03b2 = -0.72 and \u03b2 = -0.60, for Burke-Fahn-Marsden movement and disability scale, respectively [both P < 0.001]).Concl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Burke-Fahn-Marsden Dystonia Rating Scale is a universally applied instrument for the quantitative assessment of dystonia in both children and adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "healthy children, assessment of physiologically immature motor performances by the Burke-Fahn-Marsden movement and disability scales showed an association between the outcomes of both scales and age (until 16 years and 12 years of age, \u03b2 = -0.72 and \u03b2 = -0.60, for Burke-Fahn-Marsden movement and disability scale, re",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dependent of that, parents scored their children's functional motor development according to the Burke-Fahn-Marsden disability scale in another 52 healthy children (4-16 years of age; 2",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30838251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "bral palsy. Today, the Burke-Fahn-Marsden Dystonia Rating Scale (BFM) is mostly used to assess dystonia in children with inherit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32796550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ons. The Burke-Fahn-Marsden Dystonia Rating Scale-movement (BFM-M) evaluates dystonia impairment, but may not reflect functional abi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616635",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "r at least 6 months. Motor function was assessed using the Burke-Fahn-Marsden Dystonia Movement and Disability scales and the Barry Albright Dystonia Scale.RESULTS: By 6 months, significant improvement was observed in the Burke-Fahn-Marsden Dystonia Movement scale (P=.004), the Burke-Fahn-Marsden Dystonia Disability scale (P=.027), and the Barry Albright Dystonia Scale (P=.029) for the whole cohort (n=14) and in the patients treated before skeletal maturity (group 1; n=8): Burke-Fahn-Marsden Dystonia Movement scale, P=.012; Burke-Fahn-Marsden Dystonia Disability scale, P=.020; and Barry Albright Dystonia Scale, P=.027.CONCLUSIONS: Deep brain stimulation may offer an effective treatment option for cerebral palsy-related dystonia, especially",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The preoperative evaluation in dystonia aims at characterizing the severity and topography of motor symptoms in patients, who have previously been selected for deep brain stimulation (DBS).METHODS: The literature search was performed using PubMed, CINAHL, and the Cochrane Collaborative databases.RESULTS: Commonly used scales for clinical assessment are the Burke-Fahn-Marsden dystonia rating scale for generalized dystonia and the Toronto Western Spasmodic Torticolli",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21692107",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "modic Torticollis Rating Scale). The presence and severity of dystonia were scored by four independent neurologists using the Burke-Fahn-Marsden Dystonia Rating Scale and Unified H",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28661018",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "r areas. The aim is to demonstrate that in some cases of secondary dystonia, the sole use of impairment level measures, such as the Burke-Fahn-Marsden Dystonia Rating Scale, may be insufficient to fully evaluate outcome following deep brain stimulation.METHODS: Six paediatric cases who underwent deep brain stimulation surgery with a minimum of one year follow up were selected on the basis of apparent non-response to deep brain stimulation, defined as a clinically insignificant change in the Burke-Fahn-Marsden Dystonia Movement Scale (<20%), but where other evaluation measures demonstrated clinical efficacy across several domains.RESULTS: Despite no significant change in Burke-Fahn-Marsden Dystonia Rating Scale scores following deep brain stimulation, parallel outcome measures demonstrated significant benefit in a range of child and family-centred goal areas including: pain and comfort, school attendance, seating tolerance, access to assistive technology and in some cases carer burden.CONCLUSIONS: Sole use of impairment-focused measures, are limited in scope to evaluate outcome following deep brain stimulati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BFM) scale. However, the reliability of this tool has rarely been evaluated and its use in a multicenter study has never been assessed prospectively.PURPOSE: To evaluate the concordance between three unblinded clinical raters and one single-blinded rater for 10 prospective series of ratings on the BFM scale in 22 dystonic patients of the SPIDY study.METHODS: Ten assessments on the BFM scale were performed under various stimulation conditions at different time points (before surgery and 1, 3,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274034",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}